Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib+Pemetrexed/Carboplatin in EGFR+ NSCLC Failed to Prior Lazertinib
NCT05786430Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Apr 2023
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of lazertinib, pemetrexed and carboplatin, sponsored by Yonsei University. Started Apr 2023; status: completed.
02
Drugs
lazertinibpemetrexedcarboplatin
Beyond the preview
Go deeper on NCT05786430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786430.